Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADU-1805 Monotherapy and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT05856981Phase 1Recruiting
- Sponsor
- Sairopa
- Start
- Apr 2023
- Primary completion
- May 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of ADU-1805 in solid tumor, colorectal cancer (CRC), endometrial cancer (EC) and 2 more (3 arms), sponsored by Sairopa. Primary endpoints: Dose Limiting Toxicity at 21 days, Treatment-Emergent Adverse Events at 21 days and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
ADU-1805
03
Conditions
solid tumorcolorectal cancer (CRC)endometrial cancer (EC)renal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05856981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05856981.